NEW YORK (360Dx) – Magnolia Medical Technologies is alleging Kurin is infringing four patents covering Magnolia's blood collection device.
Last week, Magnolia amended a complaint filed in the US District Court for the District of Delaware to allege that Kurin is infringing four Magnolia patents — US Patent No. 9,855,001, US Patent No. 10,028,689, US Patent No. 10,039,483, and US Patent No. 10,220,139 — covering its blood collection platform.
The dispute began in May 2018 when Kurin sued Magnolia for allegedly making false claims about the efficacy and regulatory status of Magnolia’s Steripath blood culture collection system. Kurin markets a similar product called the Kurin Lock.
In August 2018, Magnolia announced it had filed a countersuit against Kurin alleging unfair competition and false advertising.
Magnolia said in a statement today that it will vigorously defend its technology and is seeking damages and a permanent injunction barring Kurin from making, using, selling, or offering for sale the Kurin Lock devices.
Kurin Lock has received 510(k) clearance from the US Food and Drug Administration, while Steripath has not.
In a recent statement, Kurin said that from the beginning, Magnolia said Kurin’s design did not divert enough volume or sufficiently isolate diverted blood. Now that the Kurin Lock has been proven in clinical use and hospitals are switching from Steripath to Kurin Lock, Magnolia is claiming patent infringement, Kurin said.